Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.

Scientist looking at three vaccine vials

With this agreement, the IVA aims to accelerate the supply of the vaccine and to make it available to other European countries that wish to participate in the initiative. The IVA is committed to providing equitable access to all participating countries across Europe.

As part of the agreement signed in April between the University of Oxford and AstraZeneca,  AstraZeneca continues to build a number of supply chains in parallel across the world, including for Europe. The Company is seeking to expand manufacturing capacity further and is open to collaborating with other companies in order to meet its commitment to support access to the vaccine at no profit during the pandemic.

Professor Andrew Pollard (Oxford Vaccine Group), Chief investigator of the Oxford Vaccine Trial at Oxford University said: “This major agreement between AstraZeneca and Europe’s Inclusive Vaccines Alliance will supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine in Europe. This prepares the ground for protection of more people around the world against the global threat to human health that is coronavirus, if the vaccine proves effective in the clinical trials.”

Read more on the University of Oxford website

Similar stories

Oxford-led team given £6.6m to map uncharted networks in the progression of Parkinson’s

A major new $9 million (£6.6 million) project funded by the Aligning Science Across Parkinson’s (ASAP) initiative will map the original circuits vulnerable to Parkinson’s on an unprecedented scale. It is the only UK-led ASAP project this year, and the first ever to be led by Oxford.

Tamoxifen repurposing study shows no benefit in treating deadly fungal meningitis

Hopes that tamoxifen could improve survival for a deadly form of fungal meningitis have been dashed by the results of a clinical trial conducted by University of Oxford researchers and published today in eLife.

Oxford researchers awarded funding to complete community COVID-19 antiviral trial

Researchers from the Nuffield Department of Primary Care Health Sciences, University of Oxford, have today announced that they have been awarded funding through the National Institute for Health Research (NIHR) to work with several UK universities and carry out a first-of-its-kind clinical trial, testing novel antiviral COVID-19 treatments for use early on in the illness by people in the community with COVID-19 who are at higher risk of complications.

New therapeutic targets identified to treat inflammatory bowel disease

Millions of patients with ulcerative colitis or Crohn’s disease, collectively known as inflammatory bowel disease (IBD), are given fresh hope as a new study shows why some of them do not respond to current treatments.

Oxford researchers call for an urgent re-evaluation of “weak” opioid safety profile

A new study associates dispensation doses of tramadol with increased risk of mortality, cardiovascular events, and fractures compared to the use of codeine to treat pain.

Labelling proteins through the diet gives new insights into how collagen-rich tissues change as we age

A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.